Kezar Life Sciences IncNASDAQ:KZRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5439
- TODAY'S CHANGE (%)0.0154 (2.9139%)
- Bid / Lots0.5481/ 40
- Ask / Lots0.5599/ 30
- Open / Previous Close0.5327 / 0.5285
- Day Range
- 52 Week Range
- Volume547,048
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KZR |
|---|---|---|
| 09:32 ET | 9904 | 0.535 |
| 09:34 ET | 26110 | 0.535 |
| 09:36 ET | 100 | 0.535 |
| 09:39 ET | 3000 | 0.535 |
| 09:43 ET | 3000 | 0.53261 |
| 09:45 ET | 200 | 0.5326 |
| 09:48 ET | 61000 | 0.534899 |
| 09:52 ET | 20000 | 0.534877 |
| 09:54 ET | 21469 | 0.535 |
| 09:56 ET | 1100 | 0.542 |
| 10:01 ET | 800 | 0.542 |
| 10:03 ET | 400 | 0.542 |
| 10:06 ET | 948 | 0.5421 |
| 10:08 ET | 300 | 0.5465 |
| 10:12 ET | 200 | 0.5465 |
| 10:14 ET | 11000 | 0.5416 |
| 10:17 ET | 392 | 0.546801 |
| 10:21 ET | 74758 | 0.53975 |
| 10:30 ET | 5000 | 0.541 |
| 10:32 ET | 600 | 0.5351 |
| 10:33 ET | 305 | 0.5351 |
| 10:35 ET | 100 | 0.5372 |
| 10:37 ET | 200 | 0.5368 |
| 10:39 ET | 1100 | 0.5368 |
| 10:42 ET | 1509 | 0.5383 |
| 10:51 ET | 1793 | 0.5383 |
| 10:55 ET | 8647 | 0.5406 |
| 10:57 ET | 400 | 0.5425 |
| 11:00 ET | 27350 | 0.53685 |
| 11:09 ET | 2100 | 0.5374 |
| 11:20 ET | 100 | 0.5419 |
| 11:22 ET | 100 | 0.533 |
| 11:24 ET | 300 | 0.54 |
| 11:36 ET | 100 | 0.534 |
| 11:40 ET | 200 | 0.542 |
| 11:47 ET | 100 | 0.534 |
| 11:56 ET | 100 | 0.542 |
| 12:00 ET | 1400 | 0.5419 |
| 12:02 ET | 200 | 0.5419 |
| 12:07 ET | 835 | 0.5403 |
| 12:14 ET | 600 | 0.5454 |
| 12:16 ET | 1777 | 0.5457 |
| 12:21 ET | 400 | 0.5455 |
| 12:25 ET | 12474 | 0.5408 |
| 12:27 ET | 20911 | 0.54 |
| 12:30 ET | 437 | 0.5426 |
| 12:32 ET | 1400 | 0.5396 |
| 12:38 ET | 100 | 0.5396 |
| 12:39 ET | 2900 | 0.5397 |
| 12:43 ET | 1000 | 0.5398 |
| 12:45 ET | 700 | 0.5398 |
| 12:48 ET | 3000 | 0.5398 |
| 01:06 ET | 200 | 0.5391 |
| 01:10 ET | 100 | 0.5391 |
| 01:12 ET | 13020 | 0.5392 |
| 01:14 ET | 100 | 0.5389 |
| 01:26 ET | 1798 | 0.5392 |
| 01:28 ET | 1000 | 0.5387 |
| 01:32 ET | 100 | 0.5393 |
| 01:35 ET | 2781 | 0.5388 |
| 01:37 ET | 200 | 0.5389 |
| 01:42 ET | 500 | 0.539 |
| 01:44 ET | 7000 | 0.5389 |
| 01:50 ET | 100 | 0.5388 |
| 01:51 ET | 1700 | 0.5389 |
| 01:53 ET | 1392 | 0.5389 |
| 01:57 ET | 400 | 0.5389 |
| 02:04 ET | 100 | 0.5389 |
| 02:13 ET | 375 | 0.5389 |
| 02:15 ET | 100 | 0.5382 |
| 02:20 ET | 1100 | 0.538799 |
| 02:22 ET | 1600 | 0.5383 |
| 02:27 ET | 400 | 0.5389 |
| 02:29 ET | 100 | 0.5382 |
| 02:31 ET | 100 | 0.5382 |
| 02:33 ET | 500 | 0.5389 |
| 02:36 ET | 100 | 0.5382 |
| 02:38 ET | 1040 | 0.5382 |
| 02:40 ET | 1700 | 0.5383 |
| 02:42 ET | 700 | 0.538299 |
| 02:45 ET | 900 | 0.5383 |
| 02:47 ET | 700 | 0.5382 |
| 02:51 ET | 700 | 0.5382 |
| 02:54 ET | 23409 | 0.5382 |
| 02:58 ET | 750 | 0.5381 |
| 03:00 ET | 2701 | 0.5382 |
| 03:03 ET | 22760 | 0.5381 |
| 03:05 ET | 7166 | 0.5382 |
| 03:07 ET | 400 | 0.5381 |
| 03:09 ET | 100 | 0.5381 |
| 03:12 ET | 100 | 0.5379 |
| 03:21 ET | 700 | 0.5381 |
| 03:25 ET | 700 | 0.5367 |
| 03:32 ET | 1000 | 0.5367 |
| 03:36 ET | 600 | 0.5355 |
| 03:39 ET | 204 | 0.5368 |
| 03:41 ET | 800 | 0.5381 |
| 03:43 ET | 217 | 0.5358 |
| 03:45 ET | 500 | 0.5428 |
| 03:50 ET | 500 | 0.5428 |
| 03:52 ET | 702 | 0.54279 |
| 03:54 ET | 2252 | 0.5428 |
| 03:56 ET | 200 | 0.5482 |
| 03:57 ET | 3034 | 0.5458 |
| 03:59 ET | 33170 | 0.5439 |
Sep 4, 2024
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference, from 4:01PM ET on Wednesday Sep 04, 2024 by Dow Jones
4:01PM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kezar Life Sciences Inc | 38.6M | -0.4x | --- |
LAVA Therapeutics NV | 43.4M | -1.9x | --- |
DURECT Corp | 39.7M | -2.4x | --- |
Atara Biotherapeutics Inc | 43.4M | -0.2x | --- |
Correlate Energy Corp | 22.1M | -1.0x | --- |
Bolt Biotherapeutics Inc | 22.3M | -0.4x | --- |
Company Information
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Contact Information
- Headquarters
- 4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO, CA, United States 94080-2005
- Phone
- 650-822-5600
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Graham Cooper
- Chief Executive Officer, Director
- Christopher Kirk
- Chief Financial Officer, Secretary
- Marc Belsky
- Chief Business Officer
- Nick Mordwinkin
- Chief Legal Officer
- Mark Schiller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $38.6M |
|---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 73.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.19 |
EPS | $-1.35 |
Book Value | $2.58 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 5.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,531.57% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
